Veru Inc.

1 in Phase 3

Quick facts

Phase 3 pipeline

Enzalutamide, Abiraterone · Oncology
This combination of an androgen receptor antagonist (enzalutamide) and a CYP17A1 inhibitor (abiraterone) blocks testosterone production and androgen signaling to treat hormone-sensitive prostate cancer.

Phase 2 pipeline

Veru-944

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: